my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Introduction
This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs
Features and benefits
* Gain insight into Roche's strategic outlook across the next 6 years
* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Roche over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales
Your key questions answered
* Benchmark Roche's performance against key rivals in the prescription pharmaceutical sector
* Assess the importance of Genentech-sourced products to the future top-line performance of the Roche Group
* Discover the impact of Roche's desire to re-enter the primary care market, away from its current hospital care focus
| Pharmacy / Health | Market study | |
|---|---|---|
| Year: | 2011 | |
| Publisher: | Datamonitor plc | |
| Price: | 5.70€ |
Order market study
Order the market study at markt-studie.de
Watchlist
This is where you can add this market study to your personal favourites.
Introduction Global Leisure Products industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metrics ... more
Introduction Global Leisure Facilities industry profile provides top-line qualitative and quantitative summary information including: market size (value , and forecast to 5). The profile also contains descriptions of the leading players including key financial metrics and analysis of compe ... more
Introduction In 2010, Datamonitor estimates that there were 7.4 million major abdominal surgeries in the seven major markets. This number is not expected to change significantly, growing to 8.1 million surgeries in 2020. Features and benefits * Gain insight to market potential, including ... more
Australia’s Top 20 cancer drugs to reach sales of $1 billion by 2018
The Australian oncology market’s high value and growth opportunities have made it an attractive arena for drug developers to enter. Top 20 cancer therapy brands sales totaled $545m in Australia in 2008, growing at a CAGR of 30% since 2005. Although this growth is expected to slow down consi ... more
Obesity and type 2 diabetes market closely linked but vastly different in outlook
The independent business analyst forecasts that the antidiabetics market will be worth $37 billion by 2018 up from $20 billion in 2008. This rapid market expansion presents significant opportunities for pharmaceutical companies who are able to develop new therapies to address the unmet clin ... more
Big pharmaceutical struggles to benefit from increased CVD drug usage
Pharmaceutical companies will struggle to profit from the cardiovascular disease (CVD) market over the next decade despite growing drug usage, according to Datamonitor. New research by the independent business analyst predicts that the CVD pharma market will grow from $99bn in 2008 to $107b ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
